When we analyzed the expression of GHRH receptors in PC-3 tumours, we observed that treatment with the antagonist and the inhibitor caused very weak labelling of GHRH-R, which was non-existent in the samples from the combined treatment. Here, GHRHR is linked to neoplasm.